BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dandapat A, Bosnakovski D, Hartweck LM, Arpke RW, Baltgalvis KA, Vang D, Baik J, Darabi R, Perlingeiro RC, Hamra FK, Gupta K, Lowe DA, Kyba M. Dominant lethal pathologies in male mice engineered to contain an X-linked DUX4 transgene. Cell Rep 2014;8:1484-96. [PMID: 25176645 DOI: 10.1016/j.celrep.2014.07.056] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 6.9] [Reference Citation Analysis]
Number Citing Articles
1 Azzag K, Bosnakovski D, Tungtur S, Salama P, Kyba M, Perlingeiro RCR. Transplantation of PSC-derived myogenic progenitors counteracts disease phenotypes in FSHD mice. NPJ Regen Med 2022;7:43. [PMID: 36056021 DOI: 10.1038/s41536-022-00249-0] [Reference Citation Analysis]
2 Bosnakovski D, Oyler D, Mitanoska A, Douglas M, Ener ET, Shams AS, Kyba M. Persistent Fibroadipogenic Progenitor Expansion Following Transient DUX4 Expression Provokes a Profibrotic State in a Mouse Model for FSHD. Int J Mol Sci 2022;23:1983. [PMID: 35216102 DOI: 10.3390/ijms23041983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Mocciaro E, Runfola V, Ghezzi P, Pannese M, Gabellini D. DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy. Cells 2021;10:3322. [PMID: 34943834 DOI: 10.3390/cells10123322] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Zhang Y, Nishiyama T, Olson EN, Bassel-Duby R. CRISPR/Cas correction of muscular dystrophies. Exp Cell Res 2021;408:112844. [PMID: 34571006 DOI: 10.1016/j.yexcr.2021.112844] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Mariot V, Joubert R, Le Gall L, Sidlauskaite E, Hourde C, Duddy W, Voit T, Bencze M, Dumonceaux J. RIPK3-mediated cell death is involved in DUX4-mediated toxicity in facioscapulohumeral dystrophy. J Cachexia Sarcopenia Muscle 2021. [PMID: 34687171 DOI: 10.1002/jcsm.12813] [Reference Citation Analysis]
6 Banerji CRS, Zammit PS. Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7. EMBO Mol Med 2021;13:e13695. [PMID: 34151531 DOI: 10.15252/emmm.202013695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sztretye M, Szabó L, Dobrosi N, Fodor J, Szentesi P, Almássy J, Magyar ZÉ, Dienes B, Csernoch L. From Mice to Humans: An Overview of the Potentials and Limitations of Current Transgenic Mouse Models of Major Muscular Dystrophies and Congenital Myopathies. Int J Mol Sci 2020;21:E8935. [PMID: 33255644 DOI: 10.3390/ijms21238935] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
8 DeSimone AM, Cohen J, Lek M, Lek A. Cellular and animal models for facioscapulohumeral muscular dystrophy. Dis Model Mech 2020;13:dmm046904. [PMID: 33174531 DOI: 10.1242/dmm.046904] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Le Gall L, Sidlauskaite E, Mariot V, Dumonceaux J. Therapeutic Strategies Targeting DUX4 in FSHD. J Clin Med 2020;9:E2886. [PMID: 32906621 DOI: 10.3390/jcm9092886] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
10 Derenne A, Tassin A, Nguyen TH, De Roeck E, Jenart V, Ansseau E, Belayew A, Coppée F, Declèves AE, Legrand A. Induction of a local muscular dystrophy using electroporation in vivo: an easy tool for screening therapeutics. Sci Rep 2020;10:11301. [PMID: 32647247 DOI: 10.1038/s41598-020-68135-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Lim KRQ, Maruyama R, Echigoya Y, Nguyen Q, Zhang A, Khawaja H, Sen Chandra S, Jones T, Jones P, Chen YW, Yokota T. Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy. Proc Natl Acad Sci U S A 2020;117:16509-15. [PMID: 32601200 DOI: 10.1073/pnas.1909649117] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
12 Morioka S, Sakaguchi H, Mohri H, Taniguchi-Ikeda M, Kanagawa M, Suzuki T, Miyagoe-Suzuki Y, Toda T, Saito N, Ueyama T. Congenital hearing impairment associated with peripheral cochlear nerve dysmyelination in glycosylation-deficient muscular dystrophy. PLoS Genet 2020;16:e1008826. [PMID: 32453729 DOI: 10.1371/journal.pgen.1008826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Jones TI, Chew GL, Barraza-Flores P, Schreier S, Ramirez M, Wuebbles RD, Burkin DJ, Bradley RK, Jones PL. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity. Skelet Muscle 2020;10:8. [PMID: 32278354 DOI: 10.1186/s13395-020-00227-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
14 DeSimone AM, Leszyk J, Wagner K, Emerson CP Jr. Identification of the hyaluronic acid pathway as a therapeutic target for facioscapulohumeral muscular dystrophy. Sci Adv 2019;5:eaaw7099. [PMID: 31844661 DOI: 10.1126/sciadv.aaw7099] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
15 Lee JK, Bosnakovski D, Toso EA, Dinh T, Banerjee S, Bohl TE, Shi K, Orellana K, Kyba M, Aihara H. Crystal Structure of the Double Homeodomain of DUX4 in Complex with DNA. Cell Rep 2018;25:2955-2962.e3. [PMID: 30540931 DOI: 10.1016/j.celrep.2018.11.060] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
16 Kinoshita J, Magdinier F, Padberg GW. 26th Annual Facioscapulohumeral Dystrophy International Research Congress Marseille, France, 19-20 June 2019. Neuromuscul Disord 2019;29:811-7. [PMID: 31604652 DOI: 10.1016/j.nmd.2019.08.015] [Reference Citation Analysis]
17 Pakula A, Lek A, Widrick J, Mitsuhashi H, Bugda Gwilt KM, Gupta VA, Rahimov F, Criscione J, Zhang Y, Gibbs D, Murphy Q, Manglik A, Mead L, Kunkel L. Transgenic zebrafish model of DUX4 misexpression reveals a developmental role in FSHD pathogenesis. Hum Mol Genet 2019;28:320-31. [PMID: 30307508 DOI: 10.1093/hmg/ddy348] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
18 de Greef JC, Krom YD, den Hamer B, Snider L, Hiramuki Y, van den Akker RFP, Breslin K, Pakusch M, Salvatori DCF, Slütter B, Tawil R, Blewitt ME, Tapscott SJ, van der Maarel SM. Smchd1 haploinsufficiency exacerbates the phenotype of a transgenic FSHD1 mouse model. Hum Mol Genet 2018;27:716-31. [PMID: 29281018 DOI: 10.1093/hmg/ddx437] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
19 Zhang Y, Long C, Bassel-Duby R, Olson EN. Myoediting: Toward Prevention of Muscular Dystrophy by Therapeutic Genome Editing. Physiol Rev 2018;98:1205-40. [PMID: 29717930 DOI: 10.1152/physrev.00046.2017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
20 Bosnakovski D, Gearhart MD, Toso EA, Ener ET, Choi SH, Kyba M. Low level DUX4 expression disrupts myogenesis through deregulation of myogenic gene expression. Sci Rep 2018;8:16957. [PMID: 30446688 DOI: 10.1038/s41598-018-35150-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
21 Giesige CR, Wallace LM, Heller KN, Eidahl JO, Saad NY, Fowler AM, Pyne NK, Al-Kharsan M, Rashnonejad A, Chermahini GA, Domire JS, Mukweyi D, Garwick-Coppens SE, Guckes SM, McLaughlin KJ, Meyer K, Rodino-Klapac LR, Harper SQ. AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD. JCI Insight 2018;3:123538. [PMID: 30429376 DOI: 10.1172/jci.insight.123538] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 8.3] [Reference Citation Analysis]
22 Helmbacher F. Tissue-specific activities of the Fat1 cadherin cooperate to control neuromuscular morphogenesis. PLoS Biol 2018;16:e2004734. [PMID: 29768404 DOI: 10.1371/journal.pbio.2004734] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
23 Rastall DPW, Alyaquob FS, O'Connell P, Pepelyayeva Y, Peters D, Godbehere-Roosa S, Pereira-Hicks C, Aldhamen YA, Amalfitano A. Mice expressing human ERAP1 variants associated with ankylosing spondylitis have altered T-cell repertoires and NK cell functions, as well as increased in utero and perinatal mortality. Int Immunol 2017;29:277-89. [PMID: 28814066 DOI: 10.1093/intimm/dxx035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
24 Eidahl JO, Giesige CR, Domire JS, Wallace LM, Fowler AM, Guckes SM, Garwick-Coppens SE, Labhart P, Harper SQ. Mouse Dux is myotoxic and shares partial functional homology with its human paralog DUX4. Hum Mol Genet 2016;25:4577-89. [PMID: 28173143 DOI: 10.1093/hmg/ddw287] [Cited by in Crossref: 8] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
25 Jagannathan S, Shadle SC, Resnick R, Snider L, Tawil RN, van der Maarel SM, Bradley RK, Tapscott SJ. Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells. Hum Mol Genet 2016;25:4419-31. [PMID: 28171552 DOI: 10.1093/hmg/ddw271] [Cited by in Crossref: 16] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
26 Dmitriev P, Kiseleva E, Kharchenko O, Ivashkin E, Pichugin A, Dessen P, Robert T, Coppée F, Belayew A, Carnac G, Laoudj-Chenivesse D, Lipinski M, Vasiliev A, Vassetzky YS. Dux4 controls migration of mesenchymal stem cells through the Cxcr4-Sdf1 axis. Oncotarget 2016;7:65090-108. [PMID: 27556182 DOI: 10.18632/oncotarget.11368] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
27 Jones T, Jones PL. A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy. PLoS One 2018;13:e0192657. [PMID: 29415061 DOI: 10.1371/journal.pone.0192657] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 9.3] [Reference Citation Analysis]
28 Statland JM, Tawil R. Facioscapulohumeral Muscular Dystrophy. Continuum (Minneap Minn) 2016;22:1916-31. [PMID: 27922500 DOI: 10.1212/CON.0000000000000399] [Cited by in Crossref: 16] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
29 Wallace LM, Saad NY, Pyne NK, Fowler AM, Eidahl JO, Domire JS, Griffin DA, Herman AC, Sahenk Z, Rodino-Klapac LR, Harper SQ. Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD. Mol Ther Methods Clin Dev 2018;8:121-30. [PMID: 29387734 DOI: 10.1016/j.omtm.2017.12.005] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
30 Bosnakovski D, Chan SSK, Recht OO, Hartweck LM, Gustafson CJ, Athman LL, Lowe DA, Kyba M. Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model. Nat Commun 2017;8:550. [PMID: 28916757 DOI: 10.1038/s41467-017-00730-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 9.2] [Reference Citation Analysis]
31 DeSimone AM, Pakula A, Lek A, Emerson CP Jr. Facioscapulohumeral Muscular Dystrophy. Compr Physiol 2017;7:1229-79. [PMID: 28915324 DOI: 10.1002/cphy.c160039] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
32 Campbell AE, Oliva J, Yates MP, Zhong JW, Shadle SC, Snider L, Singh N, Tai S, Hiramuki Y, Tawil R, van der Maarel SM, Tapscott SJ, Sverdrup FM. BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells. Skelet Muscle 2017;7:16. [PMID: 28870238 DOI: 10.1186/s13395-017-0134-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
33 Knopp P, Krom YD, Banerji CR, Panamarova M, Moyle LA, den Hamer B, van der Maarel SM, Zammit PS. DUX4 induces a transcriptome more characteristic of a less-differentiated cell state and inhibits myogenesis. J Cell Sci 2016;129:3816-31. [PMID: 27744317 DOI: 10.1242/jcs.180372] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 9.4] [Reference Citation Analysis]
34 Bosnakovski D, Gearhart MD, Toso EA, Recht OO, Cucak A, Jain AK, Barton MC, Kyba M. p53-independent DUX4 pathology in cell and animal models of facioscapulohumeral muscular dystrophy. Dis Model Mech 2017;10:1211-6. [PMID: 28754837 DOI: 10.1242/dmm.030064] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
35 Whiddon JL, Langford AT, Wong CJ, Zhong JW, Tapscott SJ. Conservation and innovation in the DUX4-family gene network. Nat Genet 2017;49:935-40. [PMID: 28459454 DOI: 10.1038/ng.3846] [Cited by in Crossref: 143] [Cited by in F6Publishing: 152] [Article Influence: 28.6] [Reference Citation Analysis]
36 Takacs E, Boto P, Simo E, Csuth TI, Toth BM, Raveh-amit H, Pap A, Kovács EG, Kobolak J, Benkö S, Dinnyes A, Szatmari I. Immunogenic Dendritic Cell Generation from Pluripotent Stem Cells by Ectopic Expression of Runx3. J I 2016;198:239-48. [DOI: 10.4049/jimmunol.1600034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
37 Moyle LA, Blanc E, Jaka O, Prueller J, Banerji CR, Tedesco FS, Harridge SD, Knight RD, Zammit PS. Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy. Elife 2016;5:e11405. [PMID: 27841748 DOI: 10.7554/eLife.11405] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
38 Bencsik R, Boto P, Szabó RN, Toth BM, Simo E, Bálint BL, Szatmari I. Improved transgene expression in doxycycline-inducible embryonic stem cells by repeated chemical selection or cell sorting. Stem Cell Research 2016;17:228-34. [DOI: 10.1016/j.scr.2016.08.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
39 Choi SH, Bosnakovski D, Strasser JM, Toso EA, Walters MA, Kyba M. Transcriptional Inhibitors Identified in a 160,000-Compound Small-Molecule DUX4 Viability Screen. J Biomol Screen 2016;21:680-8. [PMID: 27245141 DOI: 10.1177/1087057116651868] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
40 Caron L, Kher D, Lee KL, McKernan R, Dumevska B, Hidalgo A, Li J, Yang H, Main H, Ferri G, Petek LM, Poellinger L, Miller DG, Gabellini D, Schmidt U. A Human Pluripotent Stem Cell Model of Facioscapulohumeral Muscular Dystrophy-Affected Skeletal Muscles. Stem Cells Transl Med 2016;5:1145-61. [PMID: 27217344 DOI: 10.5966/sctm.2015-0224] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 9.3] [Reference Citation Analysis]
41 Zhang T, Lin Y, Liu J, Zhang ZG, Fu W, Guo LY, Pan L, Kong X, Zhang MK, Lu YH, Huang ZR, Xie Q, Li WH, Xu XQ. Rbm24 Regulates Alternative Splicing Switch in Embryonic Stem Cell Cardiac Lineage Differentiation. Stem Cells 2016;34:1776-89. [PMID: 26990106 DOI: 10.1002/stem.2366] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
42 Dandapat A, Perrin BJ, Cabelka C, Razzoli M, Ervasti JM, Bartolomucci A, Lowe DA, Kyba M. High Frequency Hearing Loss and Hyperactivity in DUX4 Transgenic Mice. PLoS One 2016;11:e0151467. [PMID: 26978271 DOI: 10.1371/journal.pone.0151467] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
43 Choi SH, Gearhart MD, Cui Z, Bosnakovski D, Kim M, Schennum N, Kyba M. DUX4 recruits p300/CBP through its C-terminus and induces global H3K27 acetylation changes. Nucleic Acids Res 2016;44:5161-73. [PMID: 26951377 DOI: 10.1093/nar/gkw141] [Cited by in Crossref: 79] [Cited by in F6Publishing: 83] [Article Influence: 13.2] [Reference Citation Analysis]
44 Jones TI, Parilla M, Jones PL. Transgenic Drosophila for Investigating DUX4 and FRG1, Two Genes Associated with Facioscapulohumeral Muscular Dystrophy (FSHD). PLoS One 2016;11:e0150938. [PMID: 26942723 DOI: 10.1371/journal.pone.0150938] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
45 Gannon OM, Merida de Long L, Saunders NA. DUX4 Is Derepressed in Late-Differentiating Keratinocytes in Conjunction with Loss of H3K9me3 Epigenetic Repression. J Invest Dermatol 2016;136:1299-302. [PMID: 26872601 DOI: 10.1016/j.jid.2016.01.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
46 Zhang Y, Lee JK, Toso EA, Lee JS, Choi SH, Slattery M, Aihara H, Kyba M. DNA-binding sequence specificity of DUX4. Skelet Muscle 2016;6:8. [PMID: 26823969 DOI: 10.1186/s13395-016-0080-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
47 Vilquin JT. [Not Available]. Med Sci (Paris) 2015;31 Spec No 3:30-1. [PMID: 26546929 DOI: 10.1051/medsci/201531s308] [Reference Citation Analysis]
48 Rickard AM, Petek LM, Miller DG. Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways. Hum Mol Genet 2015;24:5901-14. [PMID: 26246499 DOI: 10.1093/hmg/ddv315] [Cited by in Crossref: 97] [Cited by in F6Publishing: 100] [Article Influence: 13.9] [Reference Citation Analysis]
49 Corrado B, Ciardi G. Facioscapulohumeral distrophy and physiotherapy: a literary review. J Phys Ther Sci 2015;27:2381-5. [PMID: 26311987 DOI: 10.1589/jpts.27.2381] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
50 Lek A, Rahimov F, Jones PL, Kunkel LM. Emerging preclinical animal models for FSHD. Trends Mol Med 2015;21:295-306. [PMID: 25801126 DOI: 10.1016/j.molmed.2015.02.011] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
51 Ansseau E, Domire JS, Wallace LM, Eidahl JO, Guckes SM, Giesige CR, Pyne NK, Belayew A, Harper SQ. Aberrant splicing in transgenes containing introns, exons, and V5 epitopes: lessons from developing an FSHD mouse model expressing a D4Z4 repeat with flanking genomic sequences. PLoS One 2015;10:e0118813. [PMID: 25742305 DOI: 10.1371/journal.pone.0118813] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
52 Feeney SJ, McGrath MJ, Sriratana A, Gehrig SM, Lynch GS, D'Arcy CE, Price JT, McLean CA, Tupler R, Mitchell CA. FHL1 reduces dystrophy in transgenic mice overexpressing FSHD muscular dystrophy region gene 1 (FRG1). PLoS One 2015;10:e0117665. [PMID: 25695429 DOI: 10.1371/journal.pone.0117665] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
53 Himeda CL, Jones TI, Jones PL. Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease. Antioxid Redox Signal 2015;22:1463-82. [PMID: 25336259 DOI: 10.1089/ars.2014.6090] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]